IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (NASDAQ:ELGX), the developer and manufacturer of the Powerlink® System for the minimally invasive treatment of abdominal aortic aneurysms (AAA), today announced that results from its Powerlink XL® prospective, multi-center clinical trial met the primary endpoint of one-year post-procedure freedom from Type I proximal endoleak. Additionally, no stent graft distal migration was observed in any study patient at one year following the procedure. The trial was conducted under an Investigational Device Exemption (IDE) approved by the U.S. Food and Drug Administration (FDA) and the Powerlink XL is currently being commercially launched in the U.S.
